MacroGenics (MGNX) Competitors $1.18 -0.08 (-6.35%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. AURA, CYRX, RNAC, TSVT, AQST, TSHA, ATXS, ATYR, ATAI, and CMPSShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Aura Biosciences (AURA), Cryoport (CYRX), Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Aquestive Therapeutics (AQST), Taysha Gene Therapies (TSHA), Astria Therapeutics (ATXS), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Aura Biosciences Cryoport Cartesian Therapeutics 2seventy bio Aquestive Therapeutics Taysha Gene Therapies Astria Therapeutics Atyr PHARMA Atai Life Sciences COMPASS Pathways MacroGenics (NASDAQ:MGNX) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation and risk. Which has more risk & volatility, MGNX or AURA? MacroGenics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Do analysts prefer MGNX or AURA? MacroGenics presently has a consensus price target of $7.38, suggesting a potential upside of 492.37%. Aura Biosciences has a consensus price target of $22.75, suggesting a potential upside of 311.02%. Given MacroGenics' higher possible upside, equities analysts clearly believe MacroGenics is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the MarketBeat Community favor MGNX or AURA? MacroGenics received 400 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 62.10% of users gave MacroGenics an outperform vote while only 61.90% of users gave Aura Biosciences an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42662.10% Underperform Votes26037.90% Aura BiosciencesOutperform Votes2661.90% Underperform Votes1638.10% Which has preferable earnings and valuation, MGNX or AURA? MacroGenics has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$148.34M0.53-$9.06M-$1.08-1.15Aura BiosciencesN/AN/A-$76.41M-$1.75-3.16 Does the media prefer MGNX or AURA? In the previous week, Aura Biosciences had 7 more articles in the media than MacroGenics. MarketBeat recorded 9 mentions for Aura Biosciences and 2 mentions for MacroGenics. MacroGenics' average media sentiment score of 1.07 beat Aura Biosciences' score of 0.15 indicating that MacroGenics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aura Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is MGNX or AURA more profitable? Aura Biosciences has a net margin of 0.00% compared to MacroGenics' net margin of -69.07%. Aura Biosciences' return on equity of -41.57% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Aura Biosciences N/A -41.57%-36.43% Do institutionals and insiders hold more shares of MGNX or AURA? 96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 11.3% of MacroGenics shares are owned by company insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMacroGenics beats Aura Biosciences on 11 of the 18 factors compared between the two stocks. Remove Ads Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$79.49M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.806.8121.7017.82Price / Sales0.53225.96377.7294.61Price / CashN/A65.6738.1534.64Price / Book0.515.866.464.00Net Income-$9.06M$141.86M$3.20B$247.23M7 Day Performance-1.97%4.38%2.77%1.44%1 Month Performance-43.92%-12.76%-8.60%-6.26%1 Year Performance-92.54%-11.13%10.40%0.59% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.7217 of 5 stars$1.18-6.3%$7.38+525.0%-92.6%$74.45M$148.34M-0.75430Negative NewsGap DownAURAAura Biosciences1.9856 of 5 stars$5.52+1.7%$22.75+312.1%-26.2%$277.24MN/A-3.1950Short Interest ↑CYRXCryoport2.6691 of 5 stars$5.49+2.6%$11.83+115.5%-67.0%$274.01M$228.39M-1.621,020Analyst ForecastGap DownRNACCartesian Therapeutics1.8717 of 5 stars$10.11+1.1%$42.14+316.8%-37.0%$261.92M$38.91M-0.1964Gap DownTSVT2seventy bio2.0683 of 5 stars$4.95flat$6.67+34.7%-0.3%$259.07M$37.86M-2.66440Short Interest ↓Positive NewsHigh Trading VolumeAQSTAquestive Therapeutics1.7572 of 5 stars$2.62-3.3%$10.57+303.5%-34.8%$259.04M$57.56M-5.82160Gap DownTSHATaysha Gene Therapies2.9705 of 5 stars$1.24+1.6%$6.63+434.3%-52.3%$254.20M$8.33M1.97180Gap DownATXSAstria Therapeutics2.4512 of 5 stars$4.50-3.4%$26.60+491.1%-62.4%$253.95MN/A-2.1530Gap DownATYRAtyr PHARMA2.7176 of 5 stars$2.85+8.8%$18.60+552.6%N/A$253.25M$235,000.00-3.0353Positive NewsATAIAtai Life Sciences2.9246 of 5 stars$1.27-3.1%$10.50+726.8%-32.9%$251.85M$308,000.00-1.5780Positive NewsGap UpCMPSCOMPASS Pathways2.5403 of 5 stars$2.70-0.4%$20.20+648.1%-63.7%$250.22MN/A-1.23120Gap Up Remove Ads Related Companies and Tools Related Companies Aura Biosciences Alternatives Cryoport Alternatives Cartesian Therapeutics Alternatives 2seventy bio Alternatives Aquestive Therapeutics Alternatives Taysha Gene Therapies Alternatives Astria Therapeutics Alternatives Atyr PHARMA Alternatives Atai Life Sciences Alternatives COMPASS Pathways Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
